Dapagliflozine
Generic name
Dapagliflozine
Brand name
ATC Code
A10BK01
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
The pharmacokinetics properties in children over 10 years of age are similar to the PK properties in adults:
- Vd: 1,7 l/kg
- T½: 12,9 hours
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Type 2 diabetes mellitus |
|---|
|
Renal impaiment in children > 3 months
Adjustment in renal impairment as specified:
GFR 50-80 ml/min/1.73 m2
Dose adjustment not neededGFR 30-50 ml/min/1.73 m2
Dose adjustment not neededGFR 10-30 ml/min/1.73 m2
Avoid use.GFR < 10 ml/min/1.73 m2
A general recommendation is not providedThe complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Biguanides | ||
|---|---|---|
| A10BA02 | ||
| Sulfonylureas | ||
|---|---|---|
| A10BB01 | ||
| Combinations of oral blood glucose lowering drugs | ||
|---|---|---|
| A10BD20 | ||
| Glucagon-like peptide-1 (GLP-1) analogues | ||
|---|---|---|
| A10BJ05 | ||
| A10BJ01 | ||
| A10BJ02 | ||
| Sodium-glucose co-transporter 2 (SGLT2) inhibitors | ||
|---|---|---|
| A10BK03 | ||
References
- AstraZeneca AB, SmPC Forxiga (EU/1/12/795) 05-01-2022, www.geneesmiddeleninformatiebank.nl
- NKFK Workinggroup Acute Kidney Impairment, Extrapolation of KNMP risk analysis "Impaired renal function" for adults to children, 23 maart 20022
Changes
Therapeutic Drug Monitoring
Overdose
